Limitations, agreements, and source contact

Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) · Source last updated 2017-04-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details

The principal investigator (PI) agrees not to publish/publicly present any interim study results without the sponsor's prior written consent. The PI further agrees to provide 45 days written notice to the sponsor prior to submission for publication/presentation to permit the sponsor to review copies of abstracts or manuscripts for publication which report any results of the Study. The sponsor shall have the right to review and comment on any presentation, which shall include editorial rights.

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

point Of Contact

email

ClinicalTrialsDisclosure@merck.com

organization

Merck Sharp & Dohme Corp.

title

Senior Vice President, Global Clinical Development

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice